이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

BIOTRONIK - 죽상동맥경화증 병변 치료를 위한 Orsiro Mission 48mm SiroLimus 용출 관상동맥 스텐트 시스템의 안전성과 유효성을 평가하기 위한 전향적 다기관 단일 팔 연구 (BIOFLOW-48)

2026년 11월 4일 업데이트: Teleflex

The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) >36 mm and ≤ 44 mm in length (by visual estimate) in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm.

Patients enrolled in the United States will be followed for 2 years post index procedure with follow-up visits at 1, 6, 12 months and 2 years post index procedure. Patients enrolled outside of the United States will be followed through 5 years post index procedure with additional follow-up visits at 3 and 5 years post index procedure.

연구 개요

연구 유형

중재적

등록 (추정된)

150

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Baden-Wurttemberg
      • Mannheim, Baden-Wurttemberg, 독일, 68167
        • 모집하지 않고 적극적으로
        • Universitätsklinikum Mannheim, I. Medizinische Klinik
    • Bavaria
      • Fürth, Bavaria, 독일, 90766
        • 모집하지 않고 적극적으로
        • Klinikum Fürth
      • Würzburg, Bavaria, 독일, 97080
        • 빼는
        • Universitätsklinikum Würzburg
    • Schleswig-Holstein
      • Bad Segeberg, Schleswig-Holstein, 독일, 23795
        • 모집하지 않고 적극적으로
        • Segeberger Kliniken GmbH
    • California
      • Concord, California, 미국, 94520
        • 모병
        • John Muir Medical Center
    • Kansas
      • Wichita, Kansas, 미국, 67214
        • 모병
        • Ascension Via Christi Hospitals Wichita
    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • 모병
        • Massachusetts General Hospital
    • Michigan
      • Detroit, Michigan, 미국, 48202
        • 모병
        • Henry Ford Hospital
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • 모병
        • Barnes Jewish Hospital
    • New York
      • Manhasset, New York, 미국, 11030
        • 모병
        • North Shore University Hospital
      • New York, New York, 미국, 10032
        • 모병
        • Columbia University Irving Medical Center/New York Presbyterian Hospital
    • Texas
      • Dallas, Texas, 미국, 75226
        • 모병
        • Baylor Scott & White The Heart Hospital - Dallas
      • Kyle, Texas, 미국, 78640
        • 모병
        • Ascension Texas Cardiovascular
    • West Virginia
      • Charleston, West Virginia, 미국, 25304
        • 모병
        • Charleston Area Medical Center
    • Canton Ticino
      • Lugano, Canton Ticino, 스위스, 6900
        • 모집하지 않고 적극적으로
        • Istituto Cardiocentro Ticino
    • Canton of Basel-City
      • Basel, Canton of Basel-City, 스위스, 4031
        • 모집하지 않고 적극적으로
        • University hospital Basel
    • State of Vienna
      • Vienna, State of Vienna, 오스트리아, 1090
        • 모집하지 않고 적극적으로
        • Universitätsklinik für Innere Medizin II, Klinische Abteilung für Kardiologie, Medizinische Universität Wien
    • Styria
      • Graz, Styria, 오스트리아, 8036
        • 모집하지 않고 적극적으로
        • Klinische Abteilung für Kardiologie, Medizinische Universität Graz
    • Lower Silesian Voivodeship
      • Lubin, Lower Silesian Voivodeship, 폴란드, 59-301
        • 모집하지 않고 적극적으로
        • Miedziowe Centrum Zdrowia SA
    • Auvergne-Rhône-Alpes
      • Lyon, Auvergne-Rhône-Alpes, 프랑스, 69002
        • 모집하지 않고 적극적으로
        • Hospices Civils de Lyon - CHU de Lyon
    • Grand Est
      • Essey-lès-Nancy, Grand Est, 프랑스, 54270
        • 모집하지 않고 적극적으로
        • Clinique Louis Pasteur
    • Provence-Alpes-Côte d'Azur Region
      • Saint-Laurent-du-Var, Provence-Alpes-Côte d'Azur Region, 프랑스, 06700
        • 모집하지 않고 적극적으로
        • Institut Arnault Tzanck
    • Île-de-France Region
      • Paris, Île-de-France Region, 프랑스, 75014
        • 모집하지 않고 적극적으로
        • Hôpital Cochin - Groupe AP-HP

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Subject is ≥ 18 years of age

  2. Subject is able to understand the nature of the study and provide written informed consent.

    For sites outside of the United States: Note: For subjects presenting with STEMI and not in a position to read, interpret and sign the informed consent form, oral informed consent is required.

  3. Subject is an acceptable candidate for percutaneous coronary intervention (PCI) according to the applicable guidelines.

  4. Subject is an acceptable candidate for CABG.

  5. Subject is eligible for dual antiplatelet therapy (DAPT) according to guidelines.

  6. Subject has clinical evidence of ischemic heart disease, stable or unstable angina pectoris or documented silent ischemia.

  7. Subject is willing and able to comply with study follow-up requirements.

Angiographic inclusion criteria:

  1. Subject has only one target lesion in a native coronary artery to be treated with the investigational device.

    Note: One additional non-target lesion may be treated with a non-investigational treatment (e.g. stent, balloon angioplasty, atherectomy) with the exception of brachytherapy, if it is located in a different coronary artery. The non-target lesion must be treated first and must be deemed an angiographic success. (Angiographic success is defined by a residual diameter stenosis < 30% with TIMI 3 flow, as visually assessed by the physician, without the presence of prolonged chest pain or ECG changes consistent with MI.)

    Note: Multiple focal stenoses will be considered as a single lesion if they are amenable to treatment with a single study device.

  2. Target lesion must be > 36 mm and ≤ 44 mm in length by operator visual estimate and must be amenable to treatment with a single study device.

  3. Target vessel must have a reference vessel diameter of 2.25-4.0 mm by operator visual estimate.

  4. For sites in United States: Target lesion must be de novo or restenotic lesion in native coronary artery; restenotic lesion must have been treated with a standard PTCA only.

    For sites outside of the United States: Target lesion can be de novo, restenotic or in-stent restenotic, and must be located in a native coronary artery.

  5. Target lesion must have angiographic evidence of ≥ 50% and < 100% stenosis (by operator visual estimate which may be assisted by QCA / IVUS / OCT). Target lesion stenosis < 70% should have clinical justification for treatment as per local standards.

  6. Target vessel must have a Thrombolysis In Myocardial Infarction (TIMI) flow > 1.

For sites outside of the United States: Note: For STEMI, TIMI flow > 1 prior to stent implantation (after opening the vessel with a guide wire or a balloon).

Exclusion Criteria:

  1. For sites in United States only: Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index procedure.

    Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment.

  2. Subject is hemodynamically unstable.

  3. Subject is pregnant and/or breastfeeding or intends to become pregnant during the duration of the study.

  4. Subject has a known allergy to contrast medium that cannot be adequately pre-medicated, or any known allergy to thienopyridine, aspirin, both heparin and bivalirudin, L-605 cobalt-chromium (Co-Cr) alloy or one of its major elements (cobalt, chromium, tungsten and nickel), acrylic, fluoropolymers, silicon carbide, PLLA or sirolimus.

  5. Revascularization of any target vessel within 12 months prior to the index procedure or previous PCI of any non-target vessel within <72 hours prior to the index procedure.

  6. Future planned PCI (including staged procedure) or CABG after the index procedure.

  7. Planned surgery or dental surgical procedure within 6 months of index procedure unless dual antiplatelet therapy can be maintained throughout the peri-surgical period.

  8. History of a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure.

  9. Subjects with active bleeding disorders, active coagulopathy, or any other reason, who are ineligible for DAPT.

  10. Subject will refuse blood transfusions.

  11. Subject has a left ventricular ejection fraction (LVEF) < 30% within 6 months prior to or during the index procedure that was documented by any method.

  12. Subject is dialysis dependent or has impaired renal function (i.e., serum creatinine > 2.5 mg/dL or 221 µmol/L, determined within 7 days prior to the index procedure).

  13. Subject has a documented white blood cell count < 3,000 white blood cells/mm3 or a documented platelet count < 100,000 platelets/mm3 or > 700,000 platelets/mm3.

  14. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted).

  15. Subject is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure or has a malignancy that is not in remission.

  16. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e. triple therapy) can be maintained according to guidelines.

  17. Subject has life expectancy of < 1 year.

  18. Subject is currently participating or plans to participate in another clinical investigation with an investigational device or an investigational drug.

  19. In the investigator's opinion, subject will not be able to comply with the follow-up requirements.

Angiographic exclusion criteria:

  1. Target lesion is excluded if it meets any of the following criteria:

    1. Lesion is located within or treated through a saphenous vein graft or arterial graft.
    2. Lesion location is within the left main coronary artery.
    3. Lesion location is within 3 mm of the origin of the left anterior descending (LAD) or left circumflex (LCX) coronary arteries.
    4. Involves a side branch of > 2.0 mm in diameter that requires a two-device strategy after pre-dilatation.
    5. Lesion is totally occluded (100% stenosis).
    6. For sites in United States only: Lesion is a restenotic lesion that was previously treated with a bare metal or drug eluting stent (in-stent restenosis).
  2. Target vessel/lesion is excessively tortuous/angulated or is severely calcified, that would prevent complete inflation of an angioplasty balloon. This assessment should be based on visual estimation.

  3. Site sites in the United States: Target vessel has angiographic evidence of thrombus.

    For sites outside of the United States: Target vessel has angiographic evidence of unresolved large thrombus burden despite of thrombus aspiration.

    Note: Thrombus aspiration is left at the discretion of the implanting physician.

  4. Target vessel was treated with brachytherapy any time prior to the index procedure.

  5. Unsuccessful target lesion pre-dilatation, defined as residual stenosis > 50% (by visual estimation) and/or angiographic complications (e.g., distal embolization, side branch closure, dissection greater than National Heart, Lung, Blood Institute type C), and/or, for sites outside of the United States, coronary aneurysms.

  6. Non-target lesion is excluded if it meets any of the following criteria:

    1. Any of the target lesion angiographic exclusion criteria except for 1c
    2. Lesion is located within the target vessel.
    3. Lesion is > 36 mm by operator visual estimate.
    4. Lesion requires additional, unplanned stents to treat a complication.
    5. Lesion treatment is not deemed an angiographic success. (Angiographic success is defined by a residual diameter stenosis < 30% with TIMI 3 flow, as visually assessed by the physician, without the presence of prolonged chest pain or ECG changes consistent with MI.)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Orsiro Mission 48mm Sirolimus 용출 관상동맥 스텐트 시스템

Orsiro Mission is composed of a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Target Lesion Failure (TLF) rate at 12 months post-index procedure
기간: 12 months

The primary endpoint will be target lesion failure (TLF) rate at 12 months post-index procedure. TLF is defined as a composite of cardiac death, target vessel Q-wave or non-Q-wave myocardial infarction (TV-MI), or clinically driven target lesion revascularization (CD-TLR).

12 months

2차 결과 측정

결과 측정
측정값 설명
기간
모든 원인으로 인한 사망
기간: 인덱스 후 절차 1, 6, 12개월 및 2, 3, 5년
인덱스 후 절차 1, 6, 12개월 및 2, 3, 5년
모든 심근경색(MI)
기간: 인덱스 후 절차 1, 6, 12개월 및 2, 3, 5년
인덱스 후 절차 1, 6, 12개월 및 2, 3, 5년
심장사 또는 심근경색(MI)
기간: 인덱스 후 절차 1, 6, 12개월 및 2, 3, 5년
인덱스 후 절차 1, 6, 12개월 및 2, 3, 5년
표적 병변 혈관재형성(TLR)
기간: 인덱스 후 절차 1, 6, 12개월 및 2, 3, 5년
인덱스 후 절차 1, 6, 12개월 및 2, 3, 5년
표적 혈관 재개통(TVR)
기간: 인덱스 후 절차 1, 6, 12개월 및 2, 3, 5년
인덱스 후 절차 1, 6, 12개월 및 2, 3, 5년
Device success
기간: Hospital Discharge (6-24 hours post-index procedure)

Device success, defined as attainment of < 30% residual stenosis of the target lesion (based on operator visual estimate) using the Orsiro Mission study stent only.

Hospital Discharge (6-24 hours post-index procedure)
Procedure success
기간: Hospital Discharge (6-24 hours post-index procedure)

Procedure success, defined as attainment of < 30% residual stenosis of the target lesion (based on operator visual estimate) using the Orsiro Mission study stent only without occurrence of in-hospital major adverse cardiac events (MACE).

Hospital Discharge (6-24 hours post-index procedure)
Major cardiac adverse events (MACE) and individual MACE components
기간: 1, 6, 12 months and 2, 3, and 5 years post-index procedure

MACE is defined as a composite of all-cause death, Q-wave or non-Q-wave MI, and any clinically driven target lesion revascularization (TLR).

1, 6, 12 months and 2, 3, and 5 years post-index procedure
Target lesion failure (TLF) and individual TLF components
기간: 1, 6, 12 months and 2, 3, and 5 years post-index procedure

TLF is defined as a composite of cardiac death, target vessel Q-wave or non-Q-wave myocardial infarction (TV-MI), or clinically driven target lesion revascularization (CD-TLR).

1, 6, 12 months and 2, 3, and 5 years post-index procedure
Target vessel failure (TVF) and individual TVF components
기간: 1, 6, 12 months and 2, 3, and 5 years post-index procedure

TVF is defined as a composite of cardiac death, target vessel Q-wave or non-Q-wave myocardial infarction (TV-MI), and clinically driven target vessel revascularization (CD-TVR).

1, 6, 12 months and 2, 3, and 5 years post-index procedure
Stent thrombosis
기간: 1, 6, 12 months and 2, 3, and 5 years post-index procedure

Stent thrombosis will be assessed according to Academic Research Consortium - 2 (ARC-2) definitions.

1, 6, 12 months and 2, 3, and 5 years post-index procedure

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 7월 18일

기본 완료 (추정된)

2027년 9월 1일

연구 완료 (추정된)

2031년 9월 1일

연구 등록 날짜

최초 제출

2025년 1월 14일

QC 기준을 충족하는 최초 제출

2025년 1월 14일

처음 게시됨 (실제)

2025년 1월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 1월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

No IPD sharing is planned at this time. This study evaluates an investigational device under an FDA IDE. The sponsor may consider sharing de-identified IPD under controlled access following completion of primary endpoint analysis and regulatory review. Summary results will be reported in scientific publications and public registries.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다